Cargando…

Pathological regression of primary tumour and metastatic lymph nodes following chemotherapy in resectable OG cancer: pooled analysis of two trials

BACKGROUND: No definitive largescale data exist evaluating the role of pathologically defined regression changes within the primary tumour and lymph nodes (LN) of resected oesophagogastric (OG) adenocarcinoma following neoadjuvant chemotherapy and the impact on survival. METHODS: Data and samples fr...

Descripción completa

Detalles Bibliográficos
Autores principales: Athauda, Avani, Nankivell, Matthew, Langer, Rupert, Pritchard, Susan, Langley, Ruth E., von Loga, Katharina, Starling, Naureen, Chau, Ian, Cunningham, David, Grabsch, Heike I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10206103/
https://www.ncbi.nlm.nih.gov/pubmed/36966233
http://dx.doi.org/10.1038/s41416-023-02217-x
_version_ 1785046154122100736
author Athauda, Avani
Nankivell, Matthew
Langer, Rupert
Pritchard, Susan
Langley, Ruth E.
von Loga, Katharina
Starling, Naureen
Chau, Ian
Cunningham, David
Grabsch, Heike I.
author_facet Athauda, Avani
Nankivell, Matthew
Langer, Rupert
Pritchard, Susan
Langley, Ruth E.
von Loga, Katharina
Starling, Naureen
Chau, Ian
Cunningham, David
Grabsch, Heike I.
author_sort Athauda, Avani
collection PubMed
description BACKGROUND: No definitive largescale data exist evaluating the role of pathologically defined regression changes within the primary tumour and lymph nodes (LN) of resected oesophagogastric (OG) adenocarcinoma following neoadjuvant chemotherapy and the impact on survival. METHODS: Data and samples from two large prospective randomised trials (UK MRC OE05 and ST03) were pooled. Stained slides were available for central pathology review from 1619 patients. Mandard tumour regression grade (TRG) and regression of tumour within LNs (LNR: scored as present/absent) were assessed and correlated with overall survival (OS) using a Cox regression model. An exploratory analysis to define subgroups with distinct prognoses was conducted using a classification and regression tree (CART) analysis. RESULTS: Neither trial demonstrated a relationship between TRG score and the presence or absence of LNR. In univariable analysis, lower TRG, lower ypN stage, lower ypT stage, presence of LNR, presence of well/moderate tumour differentiation, and absence of tumour at resection margin were all associated with better OS. However, the multivariable analysis demonstrated that only ypN, ypT, grade of differentiation and resection margin (R0) were independent indicators of prognosis. Exploratory CART analysis identified six subgroups with 3-year OS ranging from 83% to 22%; with ypN stage being the most important single prognostic variable. CONCLUSIONS: Pathological LN stage within the resection specimen was the single most important determiner of survival. Our results suggest that the assessment of regression changes within the primary tumour or LNs may not be necessary to define the prognosis further.
format Online
Article
Text
id pubmed-10206103
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-102061032023-05-25 Pathological regression of primary tumour and metastatic lymph nodes following chemotherapy in resectable OG cancer: pooled analysis of two trials Athauda, Avani Nankivell, Matthew Langer, Rupert Pritchard, Susan Langley, Ruth E. von Loga, Katharina Starling, Naureen Chau, Ian Cunningham, David Grabsch, Heike I. Br J Cancer Article BACKGROUND: No definitive largescale data exist evaluating the role of pathologically defined regression changes within the primary tumour and lymph nodes (LN) of resected oesophagogastric (OG) adenocarcinoma following neoadjuvant chemotherapy and the impact on survival. METHODS: Data and samples from two large prospective randomised trials (UK MRC OE05 and ST03) were pooled. Stained slides were available for central pathology review from 1619 patients. Mandard tumour regression grade (TRG) and regression of tumour within LNs (LNR: scored as present/absent) were assessed and correlated with overall survival (OS) using a Cox regression model. An exploratory analysis to define subgroups with distinct prognoses was conducted using a classification and regression tree (CART) analysis. RESULTS: Neither trial demonstrated a relationship between TRG score and the presence or absence of LNR. In univariable analysis, lower TRG, lower ypN stage, lower ypT stage, presence of LNR, presence of well/moderate tumour differentiation, and absence of tumour at resection margin were all associated with better OS. However, the multivariable analysis demonstrated that only ypN, ypT, grade of differentiation and resection margin (R0) were independent indicators of prognosis. Exploratory CART analysis identified six subgroups with 3-year OS ranging from 83% to 22%; with ypN stage being the most important single prognostic variable. CONCLUSIONS: Pathological LN stage within the resection specimen was the single most important determiner of survival. Our results suggest that the assessment of regression changes within the primary tumour or LNs may not be necessary to define the prognosis further. Nature Publishing Group UK 2023-03-25 2023-06-15 /pmc/articles/PMC10206103/ /pubmed/36966233 http://dx.doi.org/10.1038/s41416-023-02217-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Athauda, Avani
Nankivell, Matthew
Langer, Rupert
Pritchard, Susan
Langley, Ruth E.
von Loga, Katharina
Starling, Naureen
Chau, Ian
Cunningham, David
Grabsch, Heike I.
Pathological regression of primary tumour and metastatic lymph nodes following chemotherapy in resectable OG cancer: pooled analysis of two trials
title Pathological regression of primary tumour and metastatic lymph nodes following chemotherapy in resectable OG cancer: pooled analysis of two trials
title_full Pathological regression of primary tumour and metastatic lymph nodes following chemotherapy in resectable OG cancer: pooled analysis of two trials
title_fullStr Pathological regression of primary tumour and metastatic lymph nodes following chemotherapy in resectable OG cancer: pooled analysis of two trials
title_full_unstemmed Pathological regression of primary tumour and metastatic lymph nodes following chemotherapy in resectable OG cancer: pooled analysis of two trials
title_short Pathological regression of primary tumour and metastatic lymph nodes following chemotherapy in resectable OG cancer: pooled analysis of two trials
title_sort pathological regression of primary tumour and metastatic lymph nodes following chemotherapy in resectable og cancer: pooled analysis of two trials
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10206103/
https://www.ncbi.nlm.nih.gov/pubmed/36966233
http://dx.doi.org/10.1038/s41416-023-02217-x
work_keys_str_mv AT athaudaavani pathologicalregressionofprimarytumourandmetastaticlymphnodesfollowingchemotherapyinresectableogcancerpooledanalysisoftwotrials
AT nankivellmatthew pathologicalregressionofprimarytumourandmetastaticlymphnodesfollowingchemotherapyinresectableogcancerpooledanalysisoftwotrials
AT langerrupert pathologicalregressionofprimarytumourandmetastaticlymphnodesfollowingchemotherapyinresectableogcancerpooledanalysisoftwotrials
AT pritchardsusan pathologicalregressionofprimarytumourandmetastaticlymphnodesfollowingchemotherapyinresectableogcancerpooledanalysisoftwotrials
AT langleyruthe pathologicalregressionofprimarytumourandmetastaticlymphnodesfollowingchemotherapyinresectableogcancerpooledanalysisoftwotrials
AT vonlogakatharina pathologicalregressionofprimarytumourandmetastaticlymphnodesfollowingchemotherapyinresectableogcancerpooledanalysisoftwotrials
AT starlingnaureen pathologicalregressionofprimarytumourandmetastaticlymphnodesfollowingchemotherapyinresectableogcancerpooledanalysisoftwotrials
AT chauian pathologicalregressionofprimarytumourandmetastaticlymphnodesfollowingchemotherapyinresectableogcancerpooledanalysisoftwotrials
AT cunninghamdavid pathologicalregressionofprimarytumourandmetastaticlymphnodesfollowingchemotherapyinresectableogcancerpooledanalysisoftwotrials
AT grabschheikei pathologicalregressionofprimarytumourandmetastaticlymphnodesfollowingchemotherapyinresectableogcancerpooledanalysisoftwotrials